These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 14643350)

  • 1. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
    Bymaster FP; Beedle EE; Findlay J; Gallagher PT; Krushinski JH; Mitchell S; Robertson DW; Thompson DC; Wallace L; Wong DT
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4477-80. PubMed ID: 14643350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a place for duloxetine?
    Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine pharmacology: profile of a dual monoamine modulator.
    Karpa KD; Cavanaugh JE; Lakoski JM
    CNS Drug Rev; 2002; 8(4):361-76. PubMed ID: 12481192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
    Westanmo AD; Gayken J; Haight R
    Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake.
    Boot JR; Brace G; Delatour CL; Dezutter N; Fairhurst J; Findlay J; Gallagher PT; Hoes I; Mahadevan S; Mitchell SN; Rathmell RE; Richards SJ; Simmonds RG; Wallace L; Whatton MA
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5395-9. PubMed ID: 15454233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [FDA approval for the antidepressive drug Cymbalta].
    Krankenpfl J; 2004; 42(5-6):154. PubMed ID: 15527218
    [No Abstract]   [Full Text] [Related]  

  • 8. Duloxetine: a new selective and dual-acting antidepressant.
    Bauer M; Möller HJ; Schneider E
    Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of duloxetine on painful physical symptoms associated with depression.
    Goldstein DJ; Lu Y; Detke MJ; Hudson J; Iyengar S; Demitrack MA
    Psychosomatics; 2004; 45(1):17-28. PubMed ID: 14709757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing update: why choose duloxetine for depression?
    Tobin ML
    Issues Ment Health Nurs; 2007 Jan; 28(1):117-20. PubMed ID: 17130011
    [No Abstract]   [Full Text] [Related]  

  • 11. N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
    Jonathan Fray M; Bish G; Brown AD; Fish PV; Stobie A; Wakenhut F; Whitlock GA
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4345-8. PubMed ID: 16750359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the new antidepressant duloxetine (Cymbalta) have any advantages over other antidepressant drugs?
    Miller MC
    Harv Ment Health Lett; 2004 Nov; 21(5):8. PubMed ID: 15556908
    [No Abstract]   [Full Text] [Related]  

  • 13. The development of new antidepressants: focus on duloxetine and escitalopram.
    Huffman JC; Perlis RH
    Harv Rev Psychiatry; 2003; 11(1):30-6. PubMed ID: 12866739
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain.
    Gould GG; Javors MA; Frazer A
    Biol Psychiatry; 2007 Jan; 61(2):210-5. PubMed ID: 16650830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
    Rabasseda X
    Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors.
    Wen H; Qin W; Yang G; Guo Y
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30704101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.
    Jost W; Marsalek P
    Clin Auton Res; 2004 Aug; 14(4):220-7. PubMed ID: 15316838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
    Tamiya J; Dyck B; Zhang M; Phan K; Fleck BA; Aparicio A; Jovic F; Tran JA; Vickers T; Grey J; Foster AC; Chen C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3328-32. PubMed ID: 18445525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.
    Thase ME; Tran PV; Wiltse C; Pangallo BA; Mallinckrodt C; Detke MJ
    J Clin Psychopharmacol; 2005 Apr; 25(2):132-40. PubMed ID: 15738744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical symptoms comorbid with depression and the new antidepressant duloxetine.
    Bailey KP
    J Psychosoc Nurs Ment Health Serv; 2003 Dec; 41(12):13-8. PubMed ID: 14682027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.